1. Home
  2. DMLP vs CAPR Comparison

DMLP vs CAPR Comparison

Compare DMLP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMLP

Dorchester Minerals L.P.

HOLD

Current Price

$27.00

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMLP
CAPR
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2002
2011

Fundamental Metrics

Financial Performance
Metric
DMLP
CAPR
Price
$27.00
$26.96
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
158.3K
935.1K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
10.74%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
$152,832,000.00
$22,270,465.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17,308.50
P/E Ratio
$22.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$4.30
52 Week High
$30.51
$40.37

Technical Indicators

Market Signals
Indicator
DMLP
CAPR
Relative Strength Index (RSI) 72.84 55.41
Support Level $27.09 $25.59
Resistance Level $28.20 $30.06
Average True Range (ATR) 0.64 1.64
MACD 0.06 0.20
Stochastic Oscillator 98.78 66.19

Price Performance

Historical Comparison
DMLP
CAPR

About DMLP Dorchester Minerals L.P.

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: